Rarity Bioscience

Rarity Bioscience is a Swedish biotech startup founded in 2021 with a focus on ultra-sensitive and multiplex nucleic acid assays for fast and cost-efficient mutation detection in liquid biopsies. Their precision diagnostics technology, based on a discovery by Dr. Lei Chen, PhD, offers high sensitivity, enabling patient stratification, treatment choice and monitoring, early MRD and relapse detection, and post-transplantation follow-up for optimized cancer care. Additionally, it allows for refined inclusion stratification and monitoring in clinical trials. The company recently secured a €500.00K Seed Round investment on 06 February 2023 from Novalis Biotech.

With a strong focus on biotechnology and healthcare industries, Rarity Bioscience aims to revolutionize mutation detection and patient care in the fields of research, pharma, and clinics. The company's innovative approach has the potential to significantly impact the precision medicine landscape, offering new possibilities for early detection and personalized treatment of cancer and other diseases. As the startup continues to grow and develop its technology, it is likely to attract further attention from investors and industry stakeholders seeking to capitalize on advancements in molecular diagnostics and precision medicine.